Market Rebellion TV
← Back to News

Various

Analyst Upgrades and Downgrades For the Week of November 4th

Analyst upgrades, downgrades, and more

By Justin Nugent · November 4, 2024
Analyst Upgrades and Downgrades For the Week of November 4th

November 4th

Upgrades:

  1. Bank of Nova Scotia (BNS) – TD Securities upgraded from Hold to Buy.
  2. Charter Communications (CHTR) – BofA Securities upgraded from Neutral to Buy, price target raised from $385 to $450.
  3. Entergy (ETR) – Morgan Stanley upgraded from Underweight to Equal-Weight, price target raised from $116 to $150.
  4. Keysight Technologies (KEYS) – Barclays upgraded from Equal Weight to Overweight, price target raised from $158 to $180.
  5. M/I Homes (MHO) – Wedbush upgraded from Neutral to Outperform, price target raised from $155 to $185.
  6. Peloton (PTON) – BofA Securities upgraded from Underperform to Buy, price target raised from $3.75 to $9.
  7. Roblox (RBLX) – Morgan Stanley upgraded from Equal-Weight to Overweight, price target raised from $38 to $65.
  8. USCB Financial Holdings (USCB) – Piper Sandler upgraded from Neutral to Overweight, price target raised from $17 to $20.
  9. Vertex (VERX) – Jefferies upgraded from Hold to Buy, price target raised from $35 to $50.
  10. Watts Water Technologies (WTS) – Northcoast upgraded from Neutral to Buy, no price target provided.
  11. Norwegian Cruise Line (NCLH) – Argus upgraded from Hold to Buy.
  12. AbbVie (ABBV) – Argus upgraded from Hold to Buy.
  13. MDU Resources (MDU) – Siebert Williams Shank upgraded from Hold to Buy, price target raised to $19.
  14. Disc Medicine (IRON) – Raymond James upgraded from Outperform to Strong Buy, price target raised from $66 to $110.
  15. Panasonic (PCRHY) – Macquarie upgraded from Neutral to Outperform.

Downgrades:

  1. Booz Allen Hamilton (BAH) – Jefferies downgraded from Buy to Hold, price target slightly raised from $180 to $190.
  2. Customers Bancorp (CUBI) – Keefe Bruyette downgraded from Outperform to Market Perform, price target lowered from $57 to $52.
  3. Ecolab (ECL) – UBS downgraded from Buy to Neutral, price target unchanged at $276.
  4. ESSA Pharma (EPIX) – Piper Sandler downgraded from Overweight to Neutral, price target lowered from $15 to $2.
  5. ESSA Pharma (EPIX) – Oppenheimer downgraded from Outperform to Perform.
  6. Entergy (ETR) – BofA Securities downgraded from Buy to Neutral, price target lowered from $138 to $154.
  7. Fiverr (FVRR) – BTIG Research downgraded from Buy to Neutral.
  8. Janus International Group (JBI) – Jefferies downgraded from Buy to Hold, price target lowered from $12 to $7.50.
  9. NNN REIT (NNN) – Exane BNP Paribas downgraded from Neutral to Underperform, no price target provided.
  10. STMicroelectronics (STM) – Morgan Stanley downgraded from Equal-Weight to Underweight.
  11. Cactus (WHD) – Barclays downgraded from Overweight to Equal Weight, price target lowered to $61.
  12. Dine Brands (DIN) – CL King downgraded from Buy to Neutral.
  13. Sight Sciences (SGHT) – Lake Street downgraded from Buy to Hold, price target lowered from $10 to $5.
  14. ESSA Pharma (EPIX) – Jefferies downgraded from Buy to Hold.
  15. Option Care Health (OPCH) – Goldman Sachs downgraded from Buy to Neutral, price target lowered to $27.
  16. Sibanye-Stillwater (SBSW) – HSBC Securities downgraded from Buy to Hold.
  17. Editas Medicine (EDIT) – Raymond James downgraded from Outperform to Market Perform.

Coverage Initiated:

  1. Casey’s General (CASY) – Gordon Haskett initiated coverage with a Hold rating, price target $400.
  2. KinderCare Learning Companies (KLC) – Multiple brokerages initiated coverage:
    • JP Morgan: Overweight, price target $31.
    • UBS: Buy, price target $36.
    • Barclays: Overweight, price target $38.
    • Morgan Stanley: Equal-Weight, price target $31.
    • BMO Capital Markets: Outperform, price target $34.
    • Goldman Sachs: Buy, price target $41.
    • Robert W. Baird: Neutral, price target $30.
  3. Kaspi.kz (KSPI) – Citigroup initiated coverage with a Buy rating, price target $140.
  4. Nektar Therapeutics (NKTR) – Piper Sandler initiated coverage with an Overweight rating, price target $7.
  5. Rollins (ROL) – Barclays initiated coverage with an Equal Weight rating, price target $50.
  6. Summit Therapeutics (SMMT) – JMP Securities initiated coverage with a Market Outperform rating, price target $32.
  7. Trip.com Group (TCOM) – Bernstein initiated coverage with an Outperform rating, price target $85.
  8. Instil Bio (TIL) – JMP Securities initiated coverage with a Market Perform rating.
  9. Tencent Music (TME) – Bernstein initiated coverage with an Outperform rating, price target $14.
  10. Zura Bio Limited (ZURA) – Leerink Partners initiated coverage with an Outperform rating, price target $15.
  11. Everus (ECG) – DA Davidson initiated coverage with a Neutral rating, price target $55.
  12. CLECO Corp (CNL) – Scotiabank initiated coverage with a Sector Outperform rating.